期刊文献+

“头孢沙星”对小鼠的急性毒性试验 被引量:3

Acute Toxicity Test of New Animal Antibiotic Medicine "Toubaoshaxing" in Mice
下载PDF
导出
摘要 用150只清洁级昆明系健康小鼠,进行“头孢沙星”原药1、0 g/L制剂口服及腹腔注射急性毒性试验。结果表明,其原药LD0在10 g/kg^15 g/kg之间,LD100大于15 g/kg;其10 g/L制剂LD50=527.38 mg/kg,95%可信限范围391.84 mg/kg^696.44 mg/kg。“头孢沙星”原药属于实际无毒,10 g/L制剂按2 mg/kg临床应用安全。 The acute toxicity tests of "Touhaoshaxing" and 10 g/L preparation were carried out in 150 mice. The results showed that"TouBaoShaXing" maximal tolerance dose (LD0) varied from 10 g/kg to 15 g/kg, and absolute lethal dose (LD100)〉 15 g/kg. Median lethal dose (LD50)of 10 g/L preparation was 527.38 mg/kg. The 95% certainty factor varied from 391.84 mg/kg to 696.44 mg/kg. Such a conclusion can be obtained that"Toubaoshaxing" is nontoxicity and 2 mg/kg dose of 10 g/L preparation is clinical safe.
出处 《动物医学进展》 CSCD 2006年第9期92-93,共2页 Progress In Veterinary Medicine
关键词 “头孢沙星” 急性毒性试验 小鼠 "Toubaoshaxing" acute toxicity test mouse
  • 相关文献

参考文献4

  • 1Li J Y, Lu R H,Yang A M,et al. Syntheses of novel fluoroquinolone compounds [J]. Heterocyclcommun, 2004, 10(6):447-450.
  • 2李剑勇,鲁润华.动物用氟喹诺酮类药物的研究进展概况[J].中兽医医药杂志,2004,23(6):19-23. 被引量:28
  • 3周绪正 唐峰 张继瑜 等.小鼠腹泻模型的铷备及治疗试验[J].中兽医医药杂志,2004,:365-365.
  • 4农业部兽药审评委员会办公室.兽药试验技术规范汇编[M].北京:农业部兽药审评委员会办公室,2001:2-4.

二级参考文献23

  • 1Ridgwav, G. L. , Mumtaz. G. , Gabriel. F. G. ,Oriel. J.D. The activity of ciprofloxacin and other 4 - quinolones against Chlamydia trachomatis and Mycoplasmas in vitro[J]. European Journal of Clinical Microbiology, 1984, 3:344 ~ 346.
  • 2Van Cutsem, P. M. , Babish, J.G. & Schwark, W.S.. The fluoroquinolone antimicrobials: Structure, antimicrobial activi ty, pharmacokinetics, clinical use in domestic animals and toxicity[J]. Cornell Veterinarian, 1990, 80:173 ~ 186.
  • 3Brown, S.A., Cooper, J., Gauze, J.J., Greco, D.S.,Weise, D. W. , Buck. J.M. Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug [ J ]. American Journal of Veterinary Research,1990, 51,
  • 4Drusano, G. L. ,Johnson, D. E., Rosen, M. & Standiford. H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of pseudomonas sepsis [ J ]. Antimicrobial Agents and Chemotherapy, 1993,37,481 ~490.
  • 5Wiuff, C. , Lykkesfeldt, J., Aarestrup, F. M. , Svendsen,O. Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular administrations[J]. J. Vet. Therap. , 2002, 25:335 ~342.
  • 6Darouiche, R., Perkins. B., Musher, D., Hamill, R.,Tsai, S.. Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria [ J ]. Journal of Infectious Diseases, 1990, 162:1124 ~ 1
  • 7Frazier, D. L. ,Thompson, L., Trettien, A., Evans, E. I.Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs[J]. J Vet Therap, 2000, 23:293~302.
  • 8Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F.,Birmingham. M.C. & Schentag, J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients [ J ].Antimicrobial Agents and Chemotherapy, 1993, 37: 1073~ 1081.
  • 9Bayer, A. S. , Hirano, L. & Yih, J. Development of β -lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis[J]. Antimicrobial Agents and Chemotherapy, 1988, 32,231 ~ 235.
  • 10Apley, M.D. & Upson, D.W. Regional danofloxacin lung tissue concentrations and their relationship to regional pulmonary blood flow in consolidated and nonconsolidated bovine lung[J]. American Journal of Veterinary Research, 1993,54:944 ~ 951.

共引文献30

同被引文献27

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部